CervoMed opened higher at $1.83, compared with its previous close of $1.77. In the last trading session, the stock traded between $1.73 and $2.20. It showed an upward intraday trend.
An investment of $100 made 4 years ago in CervoMed is now worth
$ 24.04
Resulting in a loss of
$ 75.96 (75.96%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
+$0.06 (+3.11%)
Day High
$2.20
Day Low
$1.73
Day Open
$1.83
Prev Close
$1.77
Volume
31,22,803
1W Return
17.21%
1M Return
-27.23%
3M Return
-40.65%
6M Return
-51.97%
1Y Return
-73.82%
Market Cap ($ Mn)
28
PE Ratio
-
PB Ratio
1.53
PEG Ratio
-
ROE
-88.99%
ROCE
-93.40%
EPS (TTM)
$-0.53
1 Week
17.21%
1 Month
-27.23%
3 Months
-40.65%
6 Months
-51.97%
9 Months
-61.98%
CervoMed reports NfL reduction in Phase 2a nfvPPA trial
CervoMed reported Phase 2a data showing a 3.1 pg/mL average drop in plasma NfL levels over 12 weeks. High-baseline NfL patients (13 participants) saw a greater reduction of 5.7 pg/mL. One participant withdrew due to elevated liver enzymes, which normalized after stopping treatment. Shares traded down 19.88% at $2.58 following the announcement.
1mo agoCervoMed to present at Cantor and Wainwright investor conferences
CervoMed management will present at the Cantor Global Healthcare Conference on September 11, 2026. The company will also participate in the H.C. Wainwright Global Investment Conference on September 15, 2026. Phase 3 trial initiation for neflamapimod in DLB depends on partnership or financing. Interim biomarker data for nfvPPA trial expected in early Q4 2026.
2mo agoCervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner
CervoMed Inc. reported a Q2 2026 net loss of $6.6M, up from $6.3M YoY, driven by a $1.8M drop in grant revenue despite $1.7M in operating cost savings. The company holds $24.9M in cash after raising $20.5M in equity. Key developments include UK ILAP designation for neflamapimod in DLB and plans for a Phase 3 partnership.
3mo agoCervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY
CervoMed's Q2 EPS of $(0.64) missed the $(0.60) estimate by 6.67%, though losses improved 8.57% YoY from $(0.70). The miss highlights short-term execution gaps despite a positive long-term trend in reducing per-share losses.
3mo agoCervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB
CervoMed Inc. secured an Innovation Passport under the UK ILAP for its DLB candidate neflamapimod, enabling accelerated regulatory collaboration with the MHRA and NHS. The designation highlights the drug's potential to address unmet needs in dementia care, supported by positive Phase 2 data showing improvements in cognitive and functional outcomes. The company is now seeking a strategic partner to fund Phase 3 development while advancing other pipeline assets in nfvPPA and ALS.
3mo agoHC Wainwright reiterates Buy on CervoMed, maintains $25 target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating for CervoMed, maintaining a price target of $25. The reiteration covers CervoMed, listed on NASDAQ under the ticker CRVO.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in CervoMed is now worth
$ 24.04
Resulting in a loss of
$ 75.96 (75.96%)
Note: Past profits do not guarantee future returns.
